Convatec Group PLC

Share Issue/Capital Change • Apr 9, 2020

National Storage Mechanism | Additional information

RNS Number : 3880J

ConvaTec Group PLC

09 April 2020

Scrip Dividend - calculation price

Reading, United Kingdom (9 April 2020)

On 27 February 2020, the Board of Directors of ConvaTec Group Plc ("ConvaTec" or "the Company") proposed a final dividend of 3.983 cents per share ("Final Dividend"), subject to approval at the forthcoming Annual General Meeting on 7 May 2020. This Final Dividend is to be paid on 14 May 2020 to shareholders on the share register as at 3 April 2020 ("Record Date"). The Final Dividend is payable in cash, in sterling to holders of ordinary shares, the chosen exchange rate for this payment is $1.287/£1.00, determined on 27 February 2020, giving a total sterling dividend of £61,389,753.69. A scrip dividend will be made available for this Final Dividend, allowing shareholders to elect to receive their dividend in the form of new ordinary shares.

The "Calculation Price" for the issue of new ordinary shares under the scrip dividend scheme is:

179.72 pence for each new ordinary share.

This is equivalent to 1 new share for approximately 58.07 shares held prior to the ex-dividend date of 2 April 2020.

The Calculation Price is the average of the middle market quotations of a ConvaTec share, derived from the London Stock Exchange Daily Official List, for the five consecutive business days from 2 April to 8 April 2020 (inclusive).

The latest date for receipt of elections to participate in the scrip dividend scheme for the Final Dividend is 21 April 2020. Shareholders must return their mandate form by 5pm (BST) or otherwise input their CREST elections to be received by the Company's registrar, Computershare, by 3pm (BST) on 21 April 2020. Elections received after this deadline will apply to subsequent dividends only. Unless revoked by you, your scrip dividend election will apply for all future dividends for which a scrip dividend is offered. Evergreen elections for CREST shareholders cannot be accepted and elections will revert to cash by default after the payment of each dividend.

Details of the scrip dividend scheme are available at www.convatecgroup.com/investors.

TIMETABLE

Key dates in respect of the scrip dividend scheme for the Final Dividend are

Ex-dividend Date	2 April 2020
Record Date	3 April 2020
Scrip calculation price determined	2-8 April 2020 (inclusive)
Scrip calculation price available and announced	9 April 2020
Mandate delivery deadline for Shares held in uncertificated form	3.00 p.m. on 21 April 2020
Mandate delivery deadline for Shares held in certificated form	5.00 p.m. on 21 April 2020
Announcement of the total amount of new shares to be issued	28 April 2020
Dividend payment date	14 May 2020
Dispatch of statement in accordance with section 7 of Scheme	14 May 2020

Rules and share certificates, CREST accounts credited/updated,

and first day of dealings in New Shares

Enquiries

Analysts and Investors

Mark Reynolds, Director Investor Relations, ConvaTec            +44 (0)7551 036 625

ir@convatec.com

Media

Buchanan: Charles Ryland / Chris Lane / Vicky Hayns             +44 (0)207 466 5000                                                                                                 

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.

# # #

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DIVSSEFSUESSEIL